Skip to main content

Table 2 RE-AIM guides evaluation of the impact and clinical effectiveness of IPV screening programs

From: Assessing the Veterans Health Administration’s response to intimate partner violence among women: protocol for a randomized hybrid type 2 implementation-effectiveness trial

RE-AIM dimension (study aim) Outcome measures Numerator Denominator Data sources
Reach (aim 1): The proportion of eligible WVs receiving IPV screening program. Proportion of WVs seen in primary care clinics during the last 3 months of each study phase who receive IPV screening WVs who receive IPV screening as indicated by documentation (templated note, clinical reminder) WVs seen in primary care clinics who are eligible for IPV screening (WVs seen in clinic with no screen in prior year) VA Corporate Data Warehouse (CDW): IPV screening status from health factors in templated notes and clinical reminders
Effectiveness (aim 2): The clinical effectiveness of IPV screening programs on disclosure and post-screening psychosocial service use. a. Proportion of eligible WVs who screen positive for IPV a. WVs who screen positive for IPV a. WVs who were screened for IPV CDW: IPV screening status, responses, and referral disposition (accept or decline referrals) from health factors in note templates and clinical reminders; psychosocial service visits based on clinic stop codes
b. Proportion of WVs accepting psychosocial service referrals who use such services within 2 months b. WVs who accepted referral and who use ≥ 1 psychosocial services within 2 months after positive screen b. WVs who screen positive for IPV and accept a referral
Adoption (aim 1): The absolute number/proportion of primary care clinics using the IPV screening program. a. Proportion of primary care clinics completing IPV screening with at least 70% of eligible WVs during evaluation periods a. Primary care clinics completing IPV screening with at least 70% of eligible WVs during evaluation periods a. All primary care clinics who saw at least one WV eligible for IPV screening during evaluation periods CDW: WV patient encounters within primary care clinics. IPV screening status from health factors in note templates and clinical reminders. IPV screening status, resource provision, and referrals offered determined by checkboxes as health factors in note templates and clinical reminders
b. Proportion of primary care clinics delivering IPV screening program to at least 70% of eligible WVs during evaluation periods, including evidence of resource provision and referral offered for those with positive screens b. Primary care clinics delivering the IPV screening program to at least 70% of eligible WVs during evaluation periods, including evidence of resource provision and referral offered for those with positive screens b. All primary care clinics who saw at least one WV eligible for IPV screening during evaluation periods
Implementation fidelity (aim 1): The extent to which IPV screening programs are conducted as intended by clinics. Proportion of clinics for whom at least 60% of WVs accepting referrals attend psychosocial services within 2 months of positive screen
Note: Additionally assessed via key informant interviews
Primary care clinics for whom at least 60% of WVs accepting referral attend 1 + psychosocial visits within the ensuing 2 months All primary care clinics who referred at least one screen-positive WV to psychosocial services CDW: IPV screening status, responses, and referral disposition (accept or decline referrals) from health factors in templated notes and clinical reminders; psychosocial service visits based on clinic stop codes
Maintenance (aims 1 and 3): The degree to which IPV screening programs are sustained over time. Repeat Reach analysis in last 3 months of study.
Note: Implementation strategies and contextual factors impacting maintenance will be assessed via survey and key informant interviews
Same as Reach analysis above, but with data collection occurring 9–12 months after IF ends Same as Reach analysis above, but with data collection occurring 9–12 months after IF ends CDW: For repeat of Reach analysis